Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol

Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol

BackgroundDiffuse interstitial myocardial fibrosis is a key common pathological manifestation in hypertensive heart disease (HHD) progressing to heart failure (HF). Angiotensin receptor–neprilysin inhibitors (ARNi), now a front-line treatment for HF, confer benefits independent of blood pressure, si...

Full description

Bibliographic Details
Main Authors: Vivian Lee, Qishi Zheng, Desiree-Faye Toh, Chee Jian Pua, Jennifer A. Bryant, Chi-Hang Lee, Stuart A. Cook, Javed Butler, Javier Díez, A. Mark Richards, Thu-Thao Le, Calvin W. L. Chin
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
myocardial fibrosis
sacubitril/valsartan
ARNi
hypertensive heart disease
heart failure
cardiovascular magnetic resonance imaging
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2023.1248468/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2023.1248468/full

Similar Items